PepRank

MOTS-c

Also: mitochondrial ORF of the 12S rRNA type-c · 'exercise in a vial'

EnergyLongevityInjection

Mitochondrial AMPK-activating peptide; vivid endurance anecdotes, allergic sensitisation reports.

Safety tier
Avoid
strict bar
Positive
42%
of 52 reports
Per month
≈ €22–88
injected
Rank
#53
of 61 research peptides

At a glance

Access
Grey market
InjectionFelt in 10 min – 1.2 h
Strict case
Borderline: recurring reports of allergic sensitisation and anaphylaxis-like events, plus no human data on the native peptide at the doses used.
Best effects
Better cardio endurance · lower exercise heart rate · energy (esp. over 40) · insulin sensitivity / fat loss (with GLP-1s)
Downsides
Fatigue/crash in some · injection-site histamine reaction · headache at high doses
Typical use
1-2 mg 3x/week or 0.5-1 mg before workouts; avoid 5-10 mg starting doses. Users report 0.83–2.1 mg/day (median 1.5 mg, n=12).
Stacked with
Stacked with
SS-31: Usually run first for 2-8 weeks as a mitochondrial 'repair' phase, then MOTS-c, or both at once; over-40 users credit the order for better results. · NAD+: The near-default companion (often 25-50 mg subq); together with SS-31 the three-part 'mito stack'. · Retatrutide or tirzepatide: Added to counter GLP-1 fatigue, which confounds most fat-loss claims; one user on 8 mg retatrutide had resting heart rate climb to 100-110 after adding it. · 5-Amino-1MQ: Paired in the same cycle for energy and fat loss; users seldom can say which compound did what.

Safety

Watch
Repeated anecdotal reports of progressive allergic sensitisation, including anaphylaxis-like reactions · No human data on the native peptide (only analogue CB4211: 20 subjects, 4 weeks) · Generic: grey-market purity
Tier by safety barStrict AvoidBalanced AvoidEvidence only Avoid
  • Seen harm2 of 3
  • Mechanism1 of 3
  • Data gap3 of 3
  • Silent harm1 of 3
  • Product3 of 3
Never if
Any previous reaction to MOTS-c, including hives or lip tingling · History of anaphylaxis or mast-cell disease · Pregnancy or breastfeeding (no human reproductive data)
Why each score
Seen harm 2/3
No study has dosed native MOTS-c, but at least four independent first-hand reports describe anaphylaxis needing emergency care or epinephrine, several after months of uneventful use, which is a consistent sensitisation pattern rather than isolated anecdotes. r/Biohackers: no more MOTS-c for me (anaphylaxis 5 minutes after first dose, 18 hours in emergency; more reports in thread) ↗r/Biohacking: found out I'm allergic to MOTS-c (hives, breathing difficulty, epinephrine, ambulance) ↗r/Peptidesource: MOTS-c anaphylactic shock after three months ↗
Mechanism 1/3
A mitochondria-derived peptide acting through AMPK and nuclear gene regulation; no pharmacological pathway to serious harm is known, and the anaphylaxis points to immunogenicity of the peptide or its impurities rather than its action. FDA PCAC briefing on MOTS-c, July 2026: no human exposure data, zero FAERS reports ↗
Data gap 3/3
FDA found no human exposure data for MOTS-c and did not count the analogue CB4211, whose 85-subject phase 1 saw no serious events. FDA PCAC briefing on MOTS-c, July 2026: no human exposure data, zero FAERS reports ↗CohBar: CB4211 (MOTS-c analogue) phase 1a/1b topline, 85 subjects, no SAEs ↗
Silent harm 1/3
Anaphylaxis is sudden and obvious, but it can arrive after months of tolerated doses, so early tolerance is no reassurance. r/Peptidesource: MOTS-c anaphylactic shock after three months ↗
Product 3/3
Grey-market injectable vials; US compounding began only with the October 2026 HHS enforcement discretion. Mendias & Awan 2026 preprint: 6,441 grey-market peptide samples, 42-71% failed quality criteria, 15% had endotoxin ↗

User reports

All 53 reports →
Users report
Many 'insane' posts: doubled cardio endurance, older users lifting like 20 years ago, strongest in over-40s and unfit people. Roughly 30% feel nothing ('placebo king'). A recurring minority get exhaustion or midday crashes, and high starting doses (5 mg) cause days of soreness or fatigue. Allergy is the dominant harm theme: injection-site welts that spread over weeks, then sudden whole-body hives or lip and throat swelling, sometimes after months on the same vial. At least four Reddit users describe emergency treatment for anaphylaxis (epinephrine, IV antihistamines, ambulance), one of them after a first 1 mg dose.
Glowing 11Positive 10Mixed 5Nothing 9Negative 7Bad reaction 10
  • r/BodyHackGuide· · 167 upvotesOriginal ↗

    Taking 1mg of MOTS-C 3x week is by far the best ROI on any peptide I tried so far.

    GlowingEnergy · 1 mg 3x/week · Injection · first dose (logged with heart-rate data)

    age 53

  • r/Biohacking· · 143 upvotesOriginal ↗

    I couldn't even do 5 min on stairmaster, max 8. Today I did 25 min and left because it was time to go eat again but I could have done 30-40 min easy. It's so addicting getting stronger.

    GlowingEnergy · Injection

    also on retatrutide 1.5-1.75 mg/week

  • r/Biohackers· · 680 upvotesOriginal ↗

    Currently at the hospital after my first shot of Mots C (1 MG) as I started experiencing anaphylaxis after 5 minutes. I had heard this could happen, but usually in high doses. Be safe everyone.

    Bad reactionEnergy · 1 mg · Injection · first dose

Where to buy

All 16 offers →
Getting it
Research-peptide vials (5-40 mg); since HHS enforcement discretion (29 Oct 2026) US 503A pharmacies may compound it. The CB4211 analogue never went past phase 1.

A month at 210–860 mcg/day costs ≈ €22–88 from Semax Polska at €3.41/mg. At the 0.83–2.1 mg/day users report, ≈ €85–220.

Cheapest from trusted shops in the EU

ShopPackPricePer mgPer monthTesting
Semax PolskaEU · PL
Trust 4/5Each product shows an Analiza Białek (Wrocław) HPLC report naming its operator Dobre Peptydy sp. z o.o. as the client, with a verification password (Semax 60 mg: 62.18 mg, 99%), and Reddit buyers since 2024 report fast, professional deliveries; the only complaints are about felt effect.Ships to France for €14, 1–5 days.COAs ↗
powder · 10 mg€34€3.41/mg≈ €22–88 a monthThird-party tested

Studies

Evidence
Animal only — One small phase 1b of an analogue
2 more studies and 3 sources

Sources

Molecule

Sequence
MRWQEMGYIFYPRKLR
Length
16 amino acids
Modifications
unmodified (16 aa, mitochondrial 12S rRNA-encoded)

Sequence

The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.

Report grades

Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.

GlowingPositiveMixedNothingNegativeBad reaction

% positive

The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.

Researcher estimate

No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.

Safety tier

Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.

Safety bar

The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.

Seen harm

Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.

Mechanism

A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.

Data gap

How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.

Silent harm

Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.

Product

The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.

Evidence

The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.

Access

How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.

Price per month

Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. Prices are in euros at ECB rates of 2026-10-29, before shipping; the shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.

Dose users report

The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.

Shop trust

Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.

Best value

Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.

Testing

Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.

Added peptide

Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.